What Are Monoclonal Antibodies?

Our body makes antibodies to fight off infection germs. Some people are not able to make these antibodies due to disease, medications, procedures, or genetic defects. Monoclonal antibodies are manufactured antibodies that act like natural antibodies. These antibodies can attach to and attack specific targets. They have the potential to be given as a prevention prior to exposure to a virus.

https://www.cancer.org/treatment/treatments-and-side-effects/treatment-types/immunotherapy/monoclonal-antibodies.html

Why Should I Care?

Covid-19 infections are still causing deaths

The CDC reports there has been over 101 million cases of Covid-19 in the United States with over 1 million deaths related to the illness. https://covid.cdc.gov/covid-data-tracker/#trends_totalcases_select_00

Covid-19 mRNA vaccines have reduced the rates of hospitalization associated with the illness, but have not been able to prevent all hospitalizations or death associated with the disease. https://covid.cdc.gov/covid-data-tracker/#vaccine-effectiveness

In order for vaccines to be effective, your body must be able to make antibodies to fight the infection. Some people who have a lowered immune function from cancer and other disease, genetic conditions or treatments such as organ transplants are unable to make enough antibodies to provide adequate protection even after receiving all of the recommended doses and boosters. In July, 2022 a CDC study found immunocompromised people account for 12.2% of all covid-19 related hospitalizations.

Monoclonal antibodies that target covid-19 spike proteins have been found effective in preventing severe infection and death from covid-19 infection in these cases. These antibodies keep the virus from being able to reproduce. Unfortunately, the Covid-19 virus can change over time creating variants. Current monoclonal antibodies can lose their ability to work on these variants, so new monoclonal antibodies must be found to treat the variants.

https://www.covid19treatmentguidelines.nih.gov/therapies/antivirals-including-antibody-products/anti-sars-cov-2-monoclonal-antibodies/#:~:text=Monoclonal%20antibodies%20(mAbs)%20that%20target,and%20subvariants%20can%20vary%20dramatically.

Participants must be 18 to 55, weigh at least 88 pounds, and have an immune deficiency risk from disease, genetics, medication or treatment effects. This is not a vaccine. This study is evaluating a pre-exposure preventive method. If you participate in this study, you would receive antibodies that bind to the COVID-19 spike protein and prevent COVID from making copies and thereby preventing disease. Of the participants, 50 percent will get the investigational antibodies in the form of 2 shots and 50 percent of participants will receive the antibodies already marketed as Evusheld. These antibodies last in the body up to 6 months following a single administration.

 

https://www.astrazeneca.com/media-centre/press-releases/2022/evusheld-approved-in-eu-for-covid-19-treatment.html
https://www.cdc.gov/mmwr/volumes/71/wr/mm7127a3.htm#T3_down

 

If you want to join our influenza study, answer the “Do You Qualify” section and fill out the contact form, and our office will give you a call and answer all of your questions. No obligations!

Our recruitment office number is 501-500-4270.

Qualifications

  • Must be at least 18 years of age.